• FirefoxInstall the new Firefox »
  •  Dow Down0.45% Nasdaq Down0.49%

    Tesaro, Inc. (TSRO)

    53.33 Down 0.06(0.11%) 4:00PM EST
    |After Hours : 53.32 Down 0.01 (0.01%) 4:36PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Tesaro, Inc.
    1000 Winter Street
    Suite 3300
    Waltham, MA 02451
    United States - Map
    Phone: 339-970-0900
    Website: http://www.tesarobio.com

    Index Membership:N/A
    Full Time Employees:N/A

    Business Summary 

    TESARO, Inc., an oncology-focused biopharmaceutical company, is engaged in the identification, acquisition, development, and commercialization of oncology therapeutics and supportive care product candidates in the United States and internationally. Its product portfolio consist of the Rolapitant, a neurokinin-1 receptor antagonist, which is in Phase 3 oral formulation and Phase 1 intravenous clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly polymerase inhibitor that has completed a Phase I clinical trial in cancer patients; and TSR-011, an orally available anaplastic lymphoma kinase inhibitor, which is in Phase 1/2 dose escalation clinical trials in cancer patients. The company was founded in 2010 and is headquartered in Waltham, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Tesaro, Inc.

    Corporate Governance 
    Tesaro, Inc.’s ISS Governance QuickScore as of Feb 1, 2015 is 4. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 3; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Leon O. Moulder Jr., M.B.A., 58
    Co-Founder, Chief Exec. Officer and Director
    Dr. Mary Lynne Hedley Ph.D., 52
    Co-Founder, Pres, Chief Operating Officer and Director
    Mr. Timothy R. Pearson , 47
    Chief Financial Officer
    Mr. Edward C. English , 48
    Principal Accounting Officer, VP and Controller
    Ms. Jennifer Davis ,
    Sr. Director of Corp. Devel. & Investor Relations
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders